A human neutralizing antibody targets the receptor binding site of SARS-CoV-2.Shi, R., Shan, C., Duan, X., Chen, Z., Liu, P., Song, J., Song, T., Bi, X., Han, C., Wu, L., Gao, G., Hu, X., Zhang, Y., Tong, Z., Huang, W., Liu, W.J., Wu, G., Zhang, B., Wang, L., Qi, J., Feng, H., Wang, F.S., Wang, Q., Gao, G.F., Yuan, Z., Yan, J.
- PubMed: 32454512
- DOI: 10.1038/s41586-020-2381-y
- Structures With Same Primary Citation
- PubMed Abstract:
An outbreak of the coronavirus disease 2019 (COVID-19) 1-3 , caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 4 spread globally. Countermeasures are needed to treat and prevent further dissemination of ...
An outbreak of the coronavirus disease 2019 (COVID-19) 1-3 , caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 4 spread globally. Countermeasures are needed to treat and prevent further dissemination of the virus. In this study, we report the isolation of 2 specific human monoclonal antibodies (MAbs) from a convalescent COVID-19 patient. CA1 and CB6 demonstrated potent SARS-CoV-2-specific neutralization activity in vitro against SARS-CoV-2. In addition, CB6 inhibited SARS-CoV-2 infection in rhesus monkeys at both prophylactic and treatment settings. Further structural studies revealed that CB6 recognizes an epitope that overlaps with angiotensin converting enzyme 2 (ACE2)-binding sites in SARS-CoV-2 receptor binding domain (RBD), thereby interfering with the virus/receptor interactions by both steric hindrance and direct interface-residue competition. Our results suggest CB6 deserves further clinical translation.
Savaid Medical School, University of Chinese Academy of Sciences, Beijing, 100049, China. firstname.lastname@example.org.